Manufacturer record
Pansun Pharmaceuticals: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
4 batches manufactured by Pansun Pharmaceuticals (Uttarakhand) were declared Not of Standard Quality between June 2019 and July 2019. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: R-21119, Ciprofloxacin Tablets IP (P-CIP 500 Tabelets) (exp Nov 2020). RDTL Chandigarh (state lab) found it not of standard quality: Identification and Assay. Listed in the July 2019 alert.
Records by type
4 records linked to Pansun Pharmaceuticals in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Ciprofloxacin Tablets IP (P-CIP 500 Tabelets) | Batch R-21119Mfg Dec 2018 · Exp Nov 2020 | Identification and AssayAssay | RDTL ChandigarhState lab | Jul 2019 |
| Ciprofloxacin Tablets IP (P-CIP 500 TABLETS) | Batch R-124Mfg Feb 2018 · Exp Jan 2020 | Identification, Uniformity of weight & AssayAssay | RDTL ChandigarhState lab | Jun 2019 |
| Ciprofloxacin HCl Tablets IP (PENCIP- 500 TABLETS) | Batch R-21719Mfg Dec 2018 · Exp Nov 2020 | Identification, & AssayAssay | RDTL ChandigarhState lab | Jun 2019 |
| Cefixime and Ofloxacin Tablets (P-XIME-O TABLETS) | Batch R-110Mfg Feb 2018 · Exp Jan 2020 | Identification, & AssayAssay | RDTL ChandigarhState lab | Jun 2019 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.